Breakthrough Paralysis Treatment
AND CONDITIONS THROUGH NEUROMODUATION
Emerging Innovation to Treat Spinal Cord Injury
ANEUVO® is a Platform and Therapy Development company focused on treating chronic injuries and conditions that have not been curable through traditional pharmaceutical approaches.
ExaStim® is a non-invasive neuromodulation system developed by ANEUVO that has received FDA Breakthrough Device Designation for treating spinal cord injury.
Emerging Innovation to Treat Spinal Cord Injury
ANEUVO® is a Platform and Therapy Development company focused on treating chronic injuries and conditions that have not been curable through traditional pharmaceutical approaches.
ExaStim® is a non-invasive neuromodulation system developed by ANEUVO that has received FDA Breakthrough Device Designation for treating spinal cord injury.
New Approaches to Treat Chronic Injuries and Diseases
An interdisciplinary team of expert engineers, renowned scientists and researchers, clinicians and physicians, collaborating on new innovations for chronic conditions and injuries.
An interdisciplinary team of expert engineers, renowned scientists and researchers, clinicians and physicians, collaborating on new innovations for chronic conditions and injuries.
Science
ANEUVO’s ExaStim platform modulates the nervous system and associated biological targets by sending electricity to regulate and reengage neural circuitries.
Understanding the Nervous System
Similar to the CNS, the ENS contains sensory, inter-, and motor neurons which allow it to function independently without the CNS, like a "second brain."
Science
ANEUVO’s ExaStim platform modulates the nervous system and associated biological targets by sending electricity to regulate and reengage neural circuitries.
Understanding the Nervous System
Similar to the CNS, the ENS contains sensory, inter-, and motor neurons which allow it to function independently without the CNS, like a "second brain."
ANEUVO is leading the way with new applications for neuromodulation including investigational treatment of paralysis due to spinal cord injury.
ANEUVO is leading the way with new applications for neuromodulation including investigational treatment of paralysis due to spinal cord injury.
Approach
Interface with the Nervous System
ANEUVO’s platform delivers therapy to biological targets through both invasive and non-invasive approaches to improve patient outcomes.
Approach
Interface with the Nervous System
ANEUVO’s platform delivers therapy to biological targets through both invasive and non-invasive approaches to improve patient outcomes.
ANEUVO has received Breakthrough Device Designation from the Food and Drug Administration
Breakthrough Device Designation (BDD) speeds development, assessment, and review of medical devices.
Receiving BDD is a step forward in ANEUVO’s mission to provide novel neuromodulation therapies for patients living with chronic conditions and injuries and is an acknowledgement ANEUVO’s advancements.
ANEUVO has received Breakthrough Device Designation from the Food and Drug Administration
Breakthrough Device Designation (BDD) speeds development, assessment, and review of medical devices.
Receiving BDD is a step forward in ANEUVO’s mission to provide novel neuromodulation therapies for patients living with chronic conditions and injuries and is an acknowledgement of ANEUVO’s advancements.
Application
Modulate the Nervous System
ANEUVO’s ExaStim aims to improve the functions and quality of life for SCI patients with paralysis. ExaStim was designed to provide patients with a non-surgical and non-invasive treatment option to help restore function.
In combination with rehabilitation, ExaStim may help patients recover lost function and discover a new normal through life-enhancing improvements.
